On October 11, 2021, Gordon Singer, who heads Elliott Investment Management's London office, took GlaxoSmithKline to task during a call with top shareholders over what he considers a lack of value creation. Board Chairman Jonathan Symonds said the Company remains committed to separating the consumer business from the pharmaceutical and vaccines business, and defended CEO Emma Walmsley, who has been criticized by Elliott in the past. In July, Elliott sent a letter to the Company board outlining recommendations to boost the Company's value.